TICKERNERD
Menu
VERUVERUHealthcare · Biotechnology

VERU Stock Forecast: Veru, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$2.44
−2.40% on the day

The 2 Wall Street analysts covering Veru, Inc. hold a median 12-month price target of $25 — +904.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 42 of 100 as at 11 Sept 2026 — in the lower half.

Market cap
$41.6M
Ticker Nerd rank
42 / 100
Median analyst target
$25
Analysts covering
2
Revenue$0.0
Operating income−$7.7M
Net income−$7.0M
Free cash flow−$5.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−7.9%
1M
−12.5%
YTD
+14.0%
1Y
−31.5%
From 52W high
−44.9%
From 52W low
+16.7%
$2.09
$4.43
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

VERU stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Veru, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 11 Sept 2026
42 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
83
Growth
80
Volatility
64
Issuance
51
Quality
48
Revisions
45
Momentum
35
Accruals
24
Value
19

Size (83): Smaller than most of the companies we track.

Value (19): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

VERU stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on VERU, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00$20.00$25.00Oct 25Jan 26Apr 26Jul 26VERUHigh $25Median $25Low $24

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says2 analysts
2 Buy0 Hold0 Sell
Low $24Median $25High $25

The green dot is the last close — the median target sits +904.1% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
4 June 2026Canaccord GenuityMaintainsBuy$25
4 June 2026Canaccord GenuityMaintainsBuy—
15 May 2026OppenheimerMaintainsOutperform—
18 Dec 2025Canaccord GenuityInitiatesBuy—
13 Aug 2025Raymond JamesMaintainsOutperform—
2 Jan 2025HC Wainwright & Co.ReiteratesBuy—
20 Dec 2024HC Wainwright & Co.ReiteratesBuy—
5 Nov 2024OppenheimerReiteratesOutperform—
14 May 2024B. Riley SecuritiesInitiatesBuy—
13 May 2024HC Wainwright & Co.ReiteratesBuy—
6 May 2024HC Wainwright & Co.MaintainsBuy—
15 Apr 2024OppenheimerReiteratesOutperform—
28 Mar 2024Raymond JamesInitiatesOutperform—
8 Feb 2024HC Wainwright & Co.ReiteratesBuy—
27 Sept 2023HC Wainwright & Co.ReiteratesBuy—
7 June 2023JefferiesUpgradeHold—
15 May 2023HC Wainwright & Co.MaintainsBuy—
8 May 2023HC Wainwright & Co.ReiteratesBuy—
12 Apr 2023HC Wainwright & Co.ReiteratesBuy—
6 Apr 2023HC Wainwright & Co.MaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. VERU appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

VERU vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Veru, Inc. returned −31.5% against +17.5% for the S&P 500, dividends included.

VERU vs S&P 500, last 12 monthsTotal return, rebased to 100
60708090100110120Oct 25Jan 26Apr 26Jul 26VERUS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

VERU analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Veru, Inc. (VERU) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.4×

Cheaper than 71% of US stocks

Price / sales
—
Price / book
1.5×

Cheaper than 55% of US stocks

EV / EBITDA
−0.7×

Cheaper than 65% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−64.5%

Higher than 18% of US stocks

Return on assets
−54.0%

Higher than 7% of US stocks

Dividend yield
11.5%

Higher than 91% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Veru, Inc. (VERU) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Veru, Inc. has a market value of $41.6M and an enterprise value of $18.5M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$13.6M.

  • Free cash flow in the twelve months to 30 June 2026: −$26.0M, after $0.0 of capital spending.

  • Shares outstanding: 17.1M.

  • Trailing P/E: 0.4×; forward P/E: −2.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 11.48%, paying out 0% of earnings.

  • Veru, Inc. employs 20 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

VERU vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
VERUVeru, Inc.$41.6M
42
ATYRaTyr Pharma, Inc.$42.2M
49
CELUCelularity, Inc.$39.9M
19
MGXMetagenomi Therapeutics, Inc.$43.6M
29
LITSLite Strategy, Inc.$39.6M
31
ATNMActinium Pharmaceuticals, Inc.$43.9M
73
CRVOCervoMed, Inc.$38.9M
29

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Veru, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest VERU news & analysis

Veru Advances Oral Sabizabulin Following Positive Preclinical Data Showing Potent Anticancer Activity in Human Daraxonrasib (Revolution Medicines' RASONQUE™) Resistant Pancreatic Cancer into a Planned Phase 2 Clinical Trial

GlobeNewsWire · 8 Sept 2026positive

Veru announced it is advancing oral sabizabulin into a planned Phase 2 clinical trial following positive preclinical data showing potent anticancer activity (IC50=18.2nM) in daraxonrasib-resistant human pancreatic cancer cells. The company noted sabizabulin had a good safety profile and promising efficacy in a previous Phase 1b/2 study of 80 subjects with castration-resistant and taxane-resistant metastatic prostate cancer.

Why it matters — This marks clinical progress for sabizabulin into a new indication, pancreatic cancer, building on encouraging preclinical efficacy against daraxonrasib resistance and prior safety data in prostate cancer.

Veru to Participate in Fireside Chat at the 2026 Cantor Global Healthcare Conference

GlobeNewsWire · 2 Sept 2026neutral

Veru Inc. announced that CEO Mitchell Steiner, M.D. will participate in a fireside chat at the 2026 Cantor Global Healthcare Conference. The company is a late clinical stage biopharmaceutical firm focused on medicines for cardiometabolic and inflammatory diseases.

Why it matters — The fireside chat gives Veru watchers an opportunity to hear directly from company leadership about its cardiometabolic and inflammatory disease programs at a major healthcare investment conference.

Veru Inc. (VERU) Q3 2026 Earnings Call Transcript

Seeking Alpha · 10 Aug 2026neutral

Seeking Alpha published the transcript of Veru, Inc.'s Q3 2026 earnings call. The item relays the company's quarterly earnings discussion.

Why it matters — A Veru watcher would care because the earnings call transcript provides insight into the company's most recent quarterly performance and management commentary.

Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress

GlobeNewsWire · 10 Aug 2026positive

Veru reported its fiscal 2026 third quarter financial results and provided an update on its Phase 2b PLATEAU clinical trial of enobosarm and semaglutide combination for high quality weight loss, noting the trial is fully enrolled with 239 patients.

Why it matters — Full enrollment of the Phase 2b PLATEAU trial marks a key clinical milestone for Veru's lead investigational weight-loss combination candidate.

Veru Announces Notice of Allowance for Key Methods of Use U.S. Patent for Enobosarm in Combination with Semaglutide for Quality Weight Loss

GlobeNewsWire · 4 Aug 2026positive

Veru announced a notice of allowance for a key U.S. methods-of-use patent covering enobosarm in combination with semaglutide for quality weight loss, providing patent protection until at least October 2044 once issued. This allowed patent adds to already issued enobosarm polymorph composition-of-matter patents and other pending methods-of-use and formulation applications.

Why it matters — A VERU watcher would care because the allowed patent extends intellectual property protection for the enobosarm plus semaglutide combination into 2044, strengthening the company's position around this weight-loss program.

FAQ

Frequently asked questions about VERU stock

What is the VERU stock price forecast for 2026-2027?

The 2 Wall Street analysts covering Veru, Inc. have a median 12-month price target of $25, with estimates ranging from $24 to $25. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is VERU stock a buy right now?

Of the 2 analysts covering Veru, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Veru, Inc. 42 out of 100 across roughly 4,600 US stocks as at 11 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank VERU?

As at 11 Sept 2026, Veru, Inc. ranks 42 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (83 of 100).

Will VERU stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +904.1% from the last close, and Ticker Nerd's factor model ranks Veru, Inc. 42 out of 100 as at 11 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the VERU stock forecast for 2030?

No analyst covering Veru, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VERU are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $24 to $25 over the next 12 months.

How has VERU stock performed over the past year?

Veru, Inc. returned -31.5% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Veru, Inc. do?

Veru Inc. is a late-stage biopharmaceutical company focused on developing and commercializing medicines for cardiometabolic and inflammatory diseases.

What is the latest news on VERU?

The most recent item we track (GlobeNewsWire, 8 Sept 2026): "Veru Advances Oral Sabizabulin Following Positive Preclinical Data Showing Potent Anticancer Activity in Human Daraxonrasib (Revolution Medicines' RASONQUE™) Resistant Pancreatic Cancer into a Planned Phase 2 Clinical Trial". Veru announced it is advancing oral sabizabulin into a planned Phase 2 clinical trial following positive preclinical data showing potent anticancer activity (IC50=18.2nM) in daraxonrasib-resistant human pancreatic cancer cells. The company noted sabizabulin had a good safety profile and promising efficacy in a previous Phase 1b/2 study of 80 subjects with castration-resistant and taxane-resistant metastatic prostate cancer.

Company

About Veru, Inc.

Veru Inc. is a late-stage biopharmaceutical company focused on developing and commercializing medicines for cardiometabolic and inflammatory diseases. The company’s current programs center on enobosarm, an oral selective androgen receptor modulator being studied for muscle preservation and body composition support in weight-loss settings, and sabizabulin, an oral anti-inflammatory candidate being developed for severe viral lung disease and other inflammatory conditions. Veru also markets FC2, a female condom designed to provide dual protection against unintended pregnancy and sexually transmitted infections. Based in Miami, Florida, Veru serves both clinical and consumer health markets through a portfolio that combines prescription drug development with sexual health products. Its work spans obesity-related care, oncology research, respiratory complications, and reproductive health, placing it at the intersection of specialty pharmaceuticals and medical consumer products.

CEO Dr. Mitchell S. Steiner F.A.C.S., M.D. · 20 employees · United States · https://verupharma.com